February 20, 2018 / 11:21 AM / 9 months ago

BRIEF-Cytodyn Reports Primary Endpoint Achieved In PRO 140 Pivotal Combination Therapy Trial In HIV Infection

Feb 20 (Reuters) - Cytodyn Inc:

* CYTODYN REPORTS PRIMARY ENDPOINT ACHIEVED IN PRO 140 PIVOTAL COMBINATION THERAPY TRIAL IN HIV INFECTION

* CYTODYN INC - TRIAL DATA SHOW A STATISTICALLY SIGNIFICANT REDUCTION IN HIV-1 RNA VIRAL LOAD OF GREATER THAN 0.5LOG WITH PRO 140 VERSUS PLACEBO

* CYTODYN INC - TO DATE, PRO 140 HAS BEEN GENERALLY WELL TOLERATED WITH NO DRUG-RELATED MAJOR ADVERSE EVENTS OR TREATMENT DISCONTINUATION REPORTED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below